# Stuart Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stuart-therapeutics

- Industry: Biotechnology
- Headquarters: Stuart, US
- Website: www.stuarttherapeutics.com
- Total disclosed funding: $11M
- Latest round: Series A (Mar 19, 2021)
- Investors on record: 3

## About

Stuart Therapeutics, Inc. is a US-based company focused on developing innovative therapies for chronic eye diseases, utilizing their proprietary PolyCol TM platform technology to repair damaged collagen in ocular tissues.Founded in 2017 and headquartered in Stuart, US, Stuart Therapeutics, Inc. specializes in the advancement of ocular therapies. The company raised USD 11.00 mn in Series A funding on March 19, 2021, led by InFocus Capital Partners, with participation from BioBrit, LLC, Mimo, and WARF Ventures. The total amount raised to date is USD 11.00 mn.Stuart Therapeutics specializes in the development of innovative therapies targeting chronic eye diseases through its proprietary platform technology, PolyCol TM. The core product offerings focus on a synthetic protein designed to repair disease-damaged helical collagen within the extracellular matrix, which plays a crucial role in maintaining healthy tissue in the eye. This technology aims to address conditions such as Dry Eye Disease, Glaucoma, and Dry Age-Related Macular Degeneration (Dry AMD) by specifically binding to and repairing compromised collagen structures. The intended end users of these therapies include patients suffering from chronic ocular conditions, healthcare providers, and ophthalmologists, primarily in the United States and Europe. By targeting previously undruggable areas of the human body, Stuart Therapeutics seeks to provide effective solutions that enhance visual function and preserve the quality of life for individuals affected by these debilitating diseases.Stuart Therapeutics generates revenue through strategic partnerships, collaborations, and licensing agreements with pharmaceutical companies and healthcare providers within the ophthalmology sector. These transactions typically involve the licensing of their PolyCol TM technology for further development and commercialization, aligning with established firms focused on eye care solutions. The company is engaged in B2B relationships where the end products are distributed through healthcare systems, specialty pharmacies, and surgical centers. Pricing structures for their offerings may vary based on the nature of agreements, potential milestones in product development, and the specific therapeutic applications addressed. The revenue model emphasizes collaborative approaches that leverage Stuart's unique technological advancements to penetrate targeted markets effectively, ensuring access to impactful care for chronic eye disease patients.Stuart Therapeutics plans to utilize the USD 11.00 mn raised in their Series A funding to conduct a planned phase 2 clinical trial for ST-100 and support research and development in ocular neuroprotection. The company is also exploring avenues for expanding into additional markets within the ophthalmology sector, with a focus on European regions by 2023, aiming to broaden their reach and impact in treating chronic eye diseases.

## Funding rounds

- Series A, Mar 19, 2021, $11M — BioBrit, Mimo Live Sales Ltda., WARF Ventures

## Investors

- BioBrit — Series A
- Mimo Live Sales Ltda. — Series A
- WARF Ventures (https://capitalatlas.ai/funds/warf-ventures) — Series A